ALVO Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals, Inc. has a net margin of -4.62% compared to Alvotech's net margin of 16.99%. Alvotech's return on equity of -- beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.

Alvotech has a consensus price target of $18.83, signalling upside risk potential of 395.61%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 43.42%. Given that Alvotech has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Alvotech is more attractive than Alnylam Pharmaceuticals, Inc..

Alvotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.361, suggesting its less volatile than the S&P 500 by 63.901%.

Alvotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alvotech pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Alvotech quarterly revenues are $113.7M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Alvotech's net income of -$5.3M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Alvotech's price-to-earnings ratio is 16.50x while Alnylam Pharmaceuticals, Inc.'s PE ratio is 141.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alvotech is 2.09x versus 11.45x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -4.62% compared to Alvotech's net margin of 20.83%. Alvotech's return on equity of -- beat Johnson & Johnson's return on equity of 34.46%.

Alvotech has a consensus price target of $18.83, signalling upside risk potential of 395.61%. On the other hand Johnson & Johnson has an analysts' consensus of $233.13 which suggests that it could fall by -5.52%. Given that Alvotech has higher upside potential than Johnson & Johnson, analysts believe Alvotech is more attractive than Johnson & Johnson.

Alvotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.338, suggesting its less volatile than the S&P 500 by 66.17%.

Alvotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.11% to investors and pays a quarterly dividend of $1.30 per share. Alvotech pays -- of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Alvotech quarterly revenues are $113.7M, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Alvotech's net income of -$5.3M is lower than Johnson & Johnson's net income of $5.1B. Notably, Alvotech's price-to-earnings ratio is 16.50x while Johnson & Johnson's PE ratio is 22.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alvotech is 2.09x versus 6.36x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Sofgen Pharma SA has a net margin of -4.62% compared to Alvotech's net margin of --. Alvotech's return on equity of -- beat Sofgen Pharma SA's return on equity of --.

Alvotech has a consensus price target of $18.83, signalling upside risk potential of 395.61%. On the other hand Sofgen Pharma SA has an analysts' consensus of -- which suggests that it could grow by 20561.16%. Given that Sofgen Pharma SA has higher upside potential than Alvotech, analysts believe Sofgen Pharma SA is more attractive than Alvotech.

Alvotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sofgen Pharma SA has a beta of 63.524, suggesting its more volatile than the S&P 500 by 6252.39%.

Alvotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sofgen Pharma SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alvotech pays -- of its earnings as a dividend. Sofgen Pharma SA pays out -- of its earnings as a dividend.

Alvotech quarterly revenues are $113.7M, which are larger than Sofgen Pharma SA quarterly revenues of --. Alvotech's net income of -$5.3M is higher than Sofgen Pharma SA's net income of --. Notably, Alvotech's price-to-earnings ratio is 16.50x while Sofgen Pharma SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alvotech is 2.09x versus 0.01x for Sofgen Pharma SA. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -4.62% compared to Alvotech's net margin of 21.74%. Alvotech's return on equity of -- beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Alvotech has a consensus price target of $18.83, signalling upside risk potential of 395.61%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $870.73 which suggests that it could grow by 13.58%. Given that Alvotech has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Alvotech is more attractive than Regeneron Pharmaceuticals, Inc..

Alvotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.484%.

Alvotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.47% to investors and pays a quarterly dividend of $0.94 per share. Alvotech pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Alvotech quarterly revenues are $113.7M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Alvotech's net income of -$5.3M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Alvotech's price-to-earnings ratio is 16.50x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alvotech is 2.09x versus 5.81x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.